시장보고서

상품코드

1709454

감염성 장염 치료 시장 : 치료 유형별, 병원체 유형별, 투여 경로별, 유통 채널별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 점유율, 예측(2025-2032년)

Infectious Enteritis Treatment Market, By Treatment Type, By Pathogen Type, By Route of Administration, By Distribution Channel, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 03월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 311 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

감염성 장염 치료제시장 규모는 2024년 4억 9,054만 달러로 평가되었고, 2025-2032년 연평균 복합 성장률(CAGR) 7.20%로 확대될 전망입니다.

감염성 장염 치료 시장 역학

세계 식중독 유행으로 인한 치료 수요 증가

식중독의 유행 증가는 감염성 장염 치료 시장의 중요한 촉진요인입니다. 오염된 음식과 물은 세균, 바이러스, 기생충 감염의 주요 원인으로 설사, 위장염 등의 증상을 유발합니다. 세계보건기구(WHO)에 따르면 식중독은 매년 수백만 명에게 영향을 미치고 있으며, 항생제, 경구보충액(ORS), 프로바이오틱스 등 효과적인 치료법에 대한 수요가 증가하고 있습니다. 급속한 도시화, 열악한 위생 환경, 안전하지 않은 식품 취급 방식이 특히 개발도상국에서 식중독의 급격한 증가에 기여하고 있습니다. 또한, 전 세계 여행과 무역으로 인해 국경을 초월한 식중독 병원체의 확산이 증가하고 있습니다. 항생제 내성균 증가는 첨단 치료법과 병용요법에 대한 연구를 더욱 촉진하고 있습니다. 위생에 대한 인식과 위생을 장려하는 공중보건 캠페인은 조기 진단율을 향상시켜 시장 성장을 가속하고 있습니다. 로타바이러스 예방접종과 같은 백신 접종 프로그램에 대한 정부 및 보건 기관의 자금 지원 증가도 바이러스성 장염의 심각한 사례를 감소시키고 있습니다. 전반적으로 식중독 발생률 증가와 관련 건강 위험은 감염성 장염 치료제시장의 성장을 가속하고 있습니다.

감염성 장염 치료제시장 : 주요 고려사항

당사의 리서치 애널리스트들이 공유한 분석에 따르면, 세계 시장은 예측 기간(2025-2032년) 동안 매년 약 7.20%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 추정됩니다.

치료 유형별로는 약수처리가 2024년 가장 높은 시장 점유율을 보였습니다.

병원체 유형별로는 2024년 박테리아가 주요 병원체 유형으로 나타났습니다.

투여 경로별로는 경구 투여가 2024년 주요 투여 경로로 나타났습니다.

유통 채널별로는 2024년 유통 채널은 병원 약국이 1위였습니다.

최종 사용자별로는 2024년 주요 최종 사용자는 병원이었습니다.

지역별로는 북미가 2024년 매출 1위를 기록했습니다.

감염성 장염 치료제시장 : 세분화 분석

세계 감염성 장염 치료 시장은 치료 유형, 병원체 유형, 투여 경로, 유통 채널, 최종 사용자, 지역에 따라 세분화됩니다.

시장은 치료 유형에 따라 약물요법, 치료제, 백신, 보조요법 등 4가지 범주로 나뉩니다. 치료제는 세균, 바이러스 및 기생충 감염 관리에 중요한 역할을 하기 때문에 감염성 장염 치료 시장에서 가장 지배적인 부문입니다. 항생제는 세균성 장염에 널리 처방되며, 항바이러스제와 항기생충제는 각각 바이러스 감염과 기생충 감염에 대응합니다. 항생제 내성균 증가로 인해 병용요법 및 차세대 항생제에 대한 수요가 더욱 증가하고 있습니다. 경구용 수액(ORS)은 장염의 흔한 합병증인 탈수증을 관리하는 데 필수적입니다. 급성 및 만성 장염 모두에서 치료제의 접근성과 효과로 인해 주요 치료 옵션으로 자리 잡았습니다. 또한, 온라인 약국 및 원격 의료 서비스의 부상으로 필수 의약품에 대한 환자의 접근성이 향상되고 있습니다.

시장은 병원체 유형에 따라 세균, 바이러스, 기생충의 세 가지 범주로 나뉩니다. 세균성 장염 치료 시장은 살모넬라, 대장균, 이질균 등 병원균에 의한 식중독의 높은 유행으로 인해 세균성 장염 치료 시장이 가장 지배적인 시장으로 부상하고 있습니다. 세균성 장염은 전 세계적으로 입원의 주요 원인으로 항생제 및 지지요법에 대한 수요가 증가하고 있습니다. 항생제 내성 균주 증가로 인해 첨단 치료법 및 약물 병용 요법에 대한 연구가 더욱 가속화되고 있습니다. 오염된 음식과 물은 특히 개발도상국에서 여전히 주요 전염원입니다. 또한, 안전하지 않은 식습관과 관련된 집단 발병은 인식 제고 및 예방 조치를 지속적으로 추진하고 있습니다. 세균 부문의 우위는 신속한 진단의 발전으로 신속한 치료 개입이 가능해짐에 따라 더욱 뒷받침되고 있습니다.

감염성 장염 치료제시장 : 지역별 분석

북미가 감염성 장염 치료 시장에서 큰 점유율을 차지하고 있는데, 이는 높은 의료 지출과 높은 의료 인프라가 원동력이 되고 있습니다. 미국은 식중독 유병률이 증가하고 있으며, 미국 질병예방통제센터(CDC)는 연간 약 4,800만 건의 식중독 환자가 발생한다고 보고하고 있습니다. 위생 및 공중보건에 대한 인식이 높아지고 영유아 로타바이러스 예방접종과 같은 강력한 백신 접종 프로그램이 시장 성장에 기여하고 있습니다. 캐나다에서도 오염된 식품 및 수자원으로 인한 장염 환자가 증가함에 따라 신속한 진단 도구와 효과적인 치료법에 대한 수요가 증가하고 있습니다. 연구 개발 활동이 활발하며, 항생제 내성 병원균에 대응하기 위한 새로운 항생제 및 프로바이오틱스에 초점을 맞추었습니다. 또한, 양호한 상환 정책과 공중 보건에 대한 인식을 지원하는 정부의 이니셔티브는 시장 확대를 촉진하고 있습니다. 원격 의료와 온라인 약국 증가 추세는 이 지역 전체에서 치료 접근성을 향상시키고 있습니다. 전반적으로 북미의 강력한 의료 시스템, 기술 발전, 예방 의학에 대한 노력은 감염성 장염 치료 시장의 성장을 가속하고 있습니다.

미국은 북미 감염성 장염 치료제시장을 독점하고 있으며, 그 원동력은 식중독의 높은 유병률과 탄탄한 의료 인프라에 있습니다. 미국 질병예방통제센터(CDC)에 따르면, 연간 약 4,800만 명이 식중독에 걸리며, 이는 항생제, 경구보충액(ORS), 프로바이오틱스 등의 치료에 대한 강력한 수요로 이어지고 있습니다. 이 나라에서는 영유아 로타바이러스 예방접종을 포함한 백신 접종 프로그램이 확립되어 있어 바이러스성 장염의 심각한 사례 감소에 도움이 되고 있습니다. 신속 PCR 검사 등 첨단 진단 기술이 조기 발견과 효과적인 치료를 돕고 있습니다. 또한, 항생제 내성 세균 감염이 증가함에 따라 새로운 치료법 및 병용 약물에 대한 연구가 진행되고 있습니다. 위생과 안전한 식습관을 장려하기 위한 정부의 이니셔티브와 공중 보건 캠페인 증가는 시장 성장을 더욱 촉진하고 있습니다. 또한, 원격 의료 및 온라인 약국 서비스의 확대로 인해 전국적으로 치료 접근성이 향상되고 있습니다. 전반적으로 미국 시장은 강력한 의료 정책, 기술 발전, 감염성 질환에 대한 인식 증가에 힘입어 성장세를 보이고 있습니다.

감염성 장염 치료제시장 : 경쟁 구도

감염성 장염 치료 시장은 경쟁이 치열하며, 여러 세계 제약사들이 의약품 개발, 백신, 지지요법에 집중하고 있습니다. 글락소 스미스클라인, 사노피, 머크 등 주요 기업들은 특히 바이러스성 장염 예방에 중요한 로타바이러스 백신 생산에서 두각을 나타내고 있습니다. 항생제 분야에서는 화이자, 존슨앤드존슨, 바이엘 등의 기업이 살모넬라균, 대장균 등 세균성 감염에 대응하고 있습니다. 노바티스, 애브비 등의 기업들은 감염 후 장내 환경 회복에 초점을 맞추고 있으며, 프로바이오틱스 요법에 대한 연구가 증가하고 있습니다. 시장에서는 세균성 장염 치료에서 우려되는 항생제 내성에 대응하기 위한 복합제 개발 경쟁이 치열하게 전개되고 있습니다. 파트너십, 합병, 인수는 각 회사가 포트폴리오를 확장하고 판매망을 강화하기 위한 일반적인 전략입니다. 또한, 로슈나 길리어드 사이언스와 같은 기업들이 조기 발견을 위한 첨단 기술을 통합하면서 신속 진단 도구에 대한 투자도 증가하고 있습니다. 신생 기업들은 개발도상국 수요를 충족시키기 위해 비용 효율적인 치료법에 초점을 맞추었습니다. 전반적으로 강력한 R&D 파이프라인, 기술 발전, 전략적 제휴가 감염성 장염 치료 시장의 경쟁 역학을 형성하고 있습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제13장 주요 벤더 분석 : 감염성 장염 치료 업계

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 개요
- GlaxoSmithKline plc
- Sanofi SA
- Johnson &Johnson
- Merck &Co., Inc.
- Pfizer Inc.
- Bayer AG
- Novartis AG
- AbbVie Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Takeda Pharmaceutical Company Limited
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Cipla Limited
- Gilead Sciences, Inc.
- Sun Pharmaceutical Industries Ltd

제14장 AnalystView의 전방위적 분석

LSH 25.05.07

REPORT HIGHLIGHT

Infectious Enteritis Treatment Market size was valued at US$ 490.54 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

The Infectious Enteritis Treatment Market focuses on medications, therapies, and interventions for managing infectious enteritis, an inflammation of the intestines caused by pathogens such as bacteria, viruses, or parasites. This condition leads to symptoms like diarrhea, abdominal pain, nausea, and vomiting. Common causes include rotavirus, norovirus, E. coli, and Salmonella. Treatment options vary based on the infection type and severity, including oral rehydration therapy (ORT), antibiotics, antivirals, and probiotics to restore gut health. Hospitals, clinics, and pharmacies are key providers of these treatments. Increased prevalence of foodborne illnesses and water contamination has fueled market demand. Advancements in rapid diagnostic tools support early detection and timely treatment. Government initiatives promoting awareness and vaccination programs, such as rotavirus immunization, are contributing to market growth. Regions with limited sanitation infrastructure experience a higher burden, driving demand for affordable and accessible treatments. Pharmaceutical companies are actively investing in research to develop targeted therapies and combination drugs to combat resistant pathogens. Overall, the market continues to expand, driven by growing healthcare needs and technological advancements in diagnostics and therapeutics.

Infectious Enteritis Treatment Market- Market Dynamics

Rising prevalence of foodborne illnesses increasing treatment demand globally.

Rising prevalence of foodborne illnesses is a significant driver for the infectious enteritis treatment market. Contaminated food and water are major sources of bacterial, viral, and parasitic infections, leading to conditions such as diarrhea and gastroenteritis. According to the World Health Organization (WHO), foodborne diseases affect millions of people annually, increasing the demand for effective treatments like antibiotics, oral rehydration solutions (ORS), and probiotics. Rapid urbanization, poor sanitation, and unsafe food handling practices contribute to the surge in foodborne illnesses, especially in developing regions. Additionally, global travel and trade have increased the spread of foodborne pathogens across borders. The rise in antibiotic-resistant strains of bacteria has further driven research into advanced therapies and combination treatments. Public health campaigns promoting awareness and hygiene have improved early diagnosis rates, boosting market growth. Increased funding from governments and health organizations for vaccination programs, such as rotavirus immunization, is also reducing severe cases of viral enteritis. Overall, the growing incidence of foodborne illnesses and the associated health risks are driving the expansion of the infectious enteritis treatment market.

Infectious Enteritis Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2025-2032)

Based on Treatment Type segmentation, Medications was predicted to show maximum market share in the year 2024

Based on Pathogen Type segmentation, bacterial was the leading Pathogen Type in 2024

Based on Route of Administration segmentation, Oral was the leading Route of Administration in 2024

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading Distribution Channel in 2024

Based on end-user segmentation, Hospitals was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Infectious Enteritis Treatment Market- Segmentation Analysis:

The Global Infectious Enteritis Treatment Market is segmented on the basis of Treatment Type, Pathogen Type, Route of Administration, Distribution Channel, End User, and Region.

The market is divided into four categories based on Treatment Type: Medications, Therapies, Vaccines, Supportive Care. Medications are the most dominant segment in the infectious enteritis treatment market, driven by their crucial role in managing bacterial, viral, and parasitic infections. Antibiotics are widely prescribed for bacterial enteritis, while antivirals and antiparasitic drugs address viral and parasitic infections, respectively. The growing prevalence of antibiotic-resistant bacteria has further boosted demand for combination therapies and new-generation antibiotics. Oral rehydration solutions (ORS) are essential for managing dehydration, a common complication of enteritis. The accessibility and effectiveness of medications in both acute and chronic cases make them a primary treatment option. Additionally, the rise of online pharmacies and telemedicine services has improved patient access to essential medications.

The market is divided into three categories based on Pathogen Type: Bacterial, Viral, Parasitic. The bacterial segment is the most dominant in the infectious enteritis treatment market, driven by the high prevalence of foodborne illnesses caused by pathogens such as Salmonella, E. coli, and Shigella. Bacterial enteritis is a leading cause of hospitalizations globally, increasing demand for antibiotics and supportive therapies. The rise of antibiotic-resistant strains has further accelerated research into advanced treatments and combination drug therapies. Contaminated food and water remain major transmission sources, especially in developing regions. Additionally, outbreaks linked to unsafe food practices continue to drive awareness and preventive measures. The bacterial segment's dominance is further supported by rapid diagnostic advancements, enabling quicker treatment interventions.

Infectious Enteritis Treatment Market- Geographical Insights

North America holds a significant share of the infectious enteritis treatment market, driven by high healthcare expenditure and advanced medical infrastructure. The United States leads the region due to a rising prevalence of foodborne illnesses, with the Centers for Disease Control and Prevention (CDC) reporting approximately 48 million foodborne illness cases annually. Increased awareness of hygiene and sanitation, along with strong vaccination programs, such as rotavirus immunization for infants, contribute to market growth. Canada is also witnessing a rise in enteritis cases, driven by contaminated food and water sources, increasing demand for rapid diagnostic tools and effective treatments. Research and development activities are robust, focusing on new antibiotics and probiotics to address antibiotic-resistant pathogens. Additionally, favorable reimbursement policies and government initiatives supporting public health awareness are boosting market expansion. The growing trend of telemedicine and online pharmacies is improving accessibility to treatments across the region. Overall, North America's strong healthcare system, technological advancements, and preventive care initiatives are driving growth in the infectious enteritis treatment market.

The United States dominates the infectious enteritis treatment market in North America, driven by a high prevalence of foodborne illnesses and robust healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC), approximately 48 million people suffer from foodborne illnesses annually, contributing to a strong demand for treatments such as antibiotics, oral rehydration solutions (ORS), and probiotics. The country has well-established vaccination programs, including rotavirus immunization for infants, which helps reduce severe cases of viral enteritis. Advanced diagnostic technologies, such as rapid PCR testing, are supporting early detection and effective treatment. Additionally, the growing issue of antibiotic-resistant bacterial infections is driving research into new therapies and combination drugs. Increased government initiatives and public health campaigns to promote hygiene and safe food practices are further supporting market growth. The expansion of telemedicine and online pharmacy services has also improved accessibility to treatments across the country. Overall, the U.S. market is propelled by strong healthcare policies, technological advancements, and increasing awareness about infectious diseases.

Infectious Enteritis Treatment Market- Competitive Landscape:

The infectious enteritis treatment market is highly competitive, with several global pharmaceutical companies focusing on drug development, vaccines, and supportive therapies. Key players like GlaxoSmithKline, Sanofi, and Merck are prominent in vaccine production, particularly for rotavirus, which is crucial in preventing viral enteritis. Companies such as Pfizer, Johnson & Johnson, and Bayer dominate the antibiotic segment, addressing bacterial infections like Salmonella and E. coli. Increasing research into probiotic therapies is driven by companies like Novartis and AbbVie, focusing on restoring gut health post-infection. The market is witnessing intense competition in developing combination drugs to combat antibiotic resistance, a growing concern in bacterial enteritis treatment. Partnerships, mergers, and acquisitions are common strategies as companies aim to expand their portfolios and enhance distribution networks. Additionally, investments in rapid diagnostic tools are increasing, with firms like Roche and Gilead Sciences integrating advanced technologies for early detection. Emerging players are focusing on cost-effective therapies to meet demand in developing regions. Overall, strong R&D pipelines, technological advancements, and strategic collaborations are shaping the competitive dynamics of the infectious enteritis treatment market.

Recent Developments:

In November 2022, GSK plc received FDA approval for a new oral-dosing applicator-only presentation of ROTARIX, its rotavirus vaccine. This advancement simplifies preparation for healthcare providers by removing the need for dose reconstitution, offering a more convenient option and enhancing GSK's business portfolio.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GlaxoSmithKline plc
Sanofi S.A.
Johnson & Johnson
Merck & Co., Inc.
Pfizer Inc.
Bayer AG
Novartis AG
AbbVie Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
AstraZeneca plc
Bristol-Myers Squibb Company
Boehringer Ingelheim International GmbH
Cipla Limited
Gilead Sciences, Inc.
Sun Pharmaceutical Industries Ltd

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

Medications
Therapies
Vaccines
Supportive Care

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY PATHOGEN TYPE- MARKET ANALYSIS, 2019 - 2032

Bacterial
Viral
Parasitic

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Intravenous (IV)
Injectable

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Clinics
Ambulatory Surgical Centers (ASCs)
Retail Pharmacies
Online Pharmacies

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Infectious Enteritis Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Infectious Enteritis Treatment Market Snippet by Treatment Type
- 2.1.2. Infectious Enteritis Treatment Market Snippet by Pathogen Type
- 2.1.3. Infectious Enteritis Treatment Market Snippet by Route of Administration
- 2.1.4. Infectious Enteritis Treatment Market Snippet by Distribution Channel
- 2.1.5. Infectious Enteritis Treatment Market Snippet by End User
- 2.1.6. Infectious Enteritis Treatment Market Snippet by Country
- 2.1.7. Infectious Enteritis Treatment Market Snippet by Region
2.2. Competitive Insights

3. Infectious Enteritis Treatment Key Market Trends

3.1. Infectious Enteritis Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Infectious Enteritis Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Infectious Enteritis Treatment Market Opportunities
3.4. Infectious Enteritis Treatment Market Future Trends

4. Infectious Enteritis Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Infectious Enteritis Treatment Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Infectious Enteritis Treatment Market Landscape

6.1. Infectious Enteritis Treatment Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Infectious Enteritis Treatment Market - By Treatment Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
- 7.1.2. Medications
- 7.1.3. Therapies
- 7.1.4. Vaccines
- 7.1.5. Supportive Care

8. Infectious Enteritis Treatment Market - By Pathogen Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Pathogen Type, 2024 & 2032 (%)
- 8.1.2. Bacterial
- 8.1.3. Viral
- 8.1.4. Parasitic

9. Infectious Enteritis Treatment Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Intravenous (IV)
- 9.1.4. Injectable

10. Infectious Enteritis Treatment Market - By Distribution Channel

10.1. Overview
- 10.1.1. Segment Share Analysis, By Pathogen Type, 2024 & 2032 (%)
- 10.1.2. Hospital Pharmacies
- 10.1.3. Retail Pharmacies
- 10.1.4. Online Pharmacies

11. Infectious Enteritis Treatment Market - By End User

11.1. Overview
- 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
- 11.1.2. Hospitals
- 11.1.3. Clinics
- 11.1.4. Ambulatory Surgical Centers (ASCs)
- 11.1.5. Retail Pharmacies
- 11.1.6. Online Pharmacies

12. Infectious Enteritis Treatment Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Infectious Enteritis Treatment Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Infectious Enteritis Treatment Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.10. UK
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.10.3. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.10.4. UK Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.3.10.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.10.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.11. France
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.11.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.11.4. France Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.12. Italy
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.12.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.12.4. Italy Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.3.12.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.12.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.13. Spain
  - 12.3.13.1. Overview
  - 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.13.3. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.13.4. Spain Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.3.13.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.13.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.14. The Netherlands
  - 12.3.14.1. Overview
  - 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.14.3. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.14.4. The Netherlands Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.3.14.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.14.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Overview
  - 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.16. Russia
  - 12.3.16.1. Overview
  - 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.16.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.16.4. Russia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.3.16.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.16.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.17. Poland
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.17.4. Poland Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.3.17.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.17.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.18. Rest of Europe
  - 12.3.18.1. Overview
  - 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.18.4. Rest of the Europe Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.3.18.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Infectious Enteritis Treatment Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.9. China
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.9.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.9.4. China Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.10. India
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.10.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.10.4. India Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.4.10.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.10.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.14. Indonesia
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.14.4. Indonesia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.15. Thailand
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.15.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.15.4. Thailand Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.4.15.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.15.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.17.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.17.4. Rest of APAC Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.17.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Infectious Enteritis Treatment Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Infectious Enteritis Treatment Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.15.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.15.4. Rest of MEA Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
  - 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.15.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Infectious Enteritis Treatment Industry

13.1. Competitive Dashboard
- 13.1.1. Competitive Benchmarking
- 13.1.2. Competitive Positioning
13.2. Company Profiles
- 13.2.1. GlaxoSmithKline plc
- 13.2.2. Sanofi S.A.
- 13.2.3. Johnson & Johnson
- 13.2.4. Merck & Co., Inc.
- 13.2.5. Pfizer Inc.
- 13.2.6. Bayer AG
- 13.2.7. Novartis AG
- 13.2.8. AbbVie Inc.
- 13.2.9. Eli Lilly and Company
- 13.2.10. F. Hoffmann-La Roche Ltd
- 13.2.11. Takeda Pharmaceutical Company Limited
- 13.2.12. AstraZeneca plc
- 13.2.13. Bristol-Myers Squibb Company
- 13.2.14. Boehringer Ingelheim International GmbH
- 13.2.15. Cipla Limited
- 13.2.16. Gilead Sciences, Inc.
- 13.2.17. Sun Pharmaceutical Industries Ltd

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us